Table 1.

Results of clinical trials for immunotherapy in patients with advanced HCC

Study	Drug	Phase	Setting	Median OS	HR for OS	Median PFS	ORR
IMbrave15042	Atezolizumab and bevacizumab vs. sorafenib	III	First-line	19.2 mo for atezolizumab and bevacizumab vs. 13.4 mo for sorafenib	0.66	6.9 mo for atezolizumab and bevacizumab vs. 4.3 mo for sorafenib	30% for atezolizumab and bevacizumab vs. 11% for sorafenib
HIMALAYA46	Durvalumab and tremelimumab or durvalumab vs. sorafenib	III	First-line	16.43 mo for STRIDE vs. 13.77 mo for sorafenib	0.78	3.78 mo for STRIDE and 3.65 mo for durvalumab vs. 4.07 for sorafenib	20.1% for STRIDE, 17% for durvalumab vs. 5.1 for sorafenib
ORIENT-3292	Sintilimab and bevacizumab biosimilar IBI305 vs. sorafenib	III	First-line	NR for Sintilimab and IBI305 vs. 10.4 mo for sorafenib	0.57	4.6 mo for Sintilimab and IBI305 vs. 2.8 mo for sorafenib	21% for Sintilimab and IBI305 vs. 4.7% for sorafenib
COSMIC-32193	Cabozantinib and atezolizumab vs. sorafenib	III	First-line	15.4 mo for cabozantinib and atezolizumab vs. 15.5 mo for sorafenib	0.90	6.8 mo for cabozantinib and atezolizumab vs. 4.2 mo for sorafenib	13% for cabozantinib and atezolizumab vs. 6% for sorafenib
CheckMate 45938	Nivolumab vs. sorafenib	III	First-line	16.4 mo for nivolumab vs. 14.7 mo for sorafenib	0.85	3.7 mo for nivolumab vs. 3.8 mo for sorafenib	15% for nivolumab and 7% for sorafenib
LEAP-00249	Lenvatinib and pembrolizumab vs. lenvatinib	III	First-line	21.2 mo for lenvatinib and pembrolizumab vs. 19 mo for lenvatinib	0.83	8.2 mo for lenvatinib and pembrolizumab vs. 8.1 mo for lenvatinib	26.1% for lenvatinib and pembrolizumab vs. 17.5% for lenvatinib
Qin, et al.94	Camrelizumab and rivoceranib vs. sorafenib	III	First-line	22.1 mo for camrelizumab and rivoceranib vs. 15.2 mo for sorafenib	0.62	5.6 mo for camrelizumab and rivoceranib vs. 3.7 mo for sorafenib	25.4% for camrelizumab and rivoceranib vs. 5.9% for sorafenib
KEYNOTE-2408	Pembrolizumab vs. BSC	III	Second-line (after sorafenib)	13.9 mo for pembrolizumab vs. 10.6 mo for BSC	0.78	3.0 mo for pembrolizumab vs. 2.8 mo for BSC	18.3% for pembrolizumab vs. 4.4% for BSC
KEYNOTE-39439	Pembrolizumab vs. placebo	III	Second-line	14.6 mo for pembrolizumab vs. 13.0 mo for placebo	0.79	2.6 mo for pembrolizumab vs. 2.3 mo for placebo	12.7% for pembrolizumab vs. 1.3% for placebo

HCC, hepatocellular carcinoma; OS, overall survival; HR, hazard ratio; PFS, progression-free survival; ORR, objective response rate; mo, months; NR, not reached; BSC, best supportive care.